CL2004000306A1 - Compuestos derivados de pirimidina sustituidas con indano; proceso para su preparacion; composicion farmaceutica que lo comprende; combinacion farmaceutica; y su uso para el tratamiento o profilaxis de una enfermedad infecciosa. - Google Patents
Compuestos derivados de pirimidina sustituidas con indano; proceso para su preparacion; composicion farmaceutica que lo comprende; combinacion farmaceutica; y su uso para el tratamiento o profilaxis de una enfermedad infecciosa.Info
- Publication number
- CL2004000306A1 CL2004000306A1 CL200400306A CL2004000306A CL2004000306A1 CL 2004000306 A1 CL2004000306 A1 CL 2004000306A1 CL 200400306 A CL200400306 A CL 200400306A CL 2004000306 A CL2004000306 A CL 2004000306A CL 2004000306 A1 CL2004000306 A1 CL 2004000306A1
- Authority
- CL
- Chile
- Prior art keywords
- profilaxis
- indano
- understands
- preparation
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03100411 | 2003-02-20 | ||
| US47501203P | 2003-06-02 | 2003-06-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2004000306A1 true CL2004000306A1 (es) | 2005-04-08 |
Family
ID=32910137
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL200400303A CL2004000303A1 (es) | 2003-02-20 | 2004-02-19 | Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih. |
| CL200400306A CL2004000306A1 (es) | 2003-02-20 | 2004-02-19 | Compuestos derivados de pirimidina sustituidas con indano; proceso para su preparacion; composicion farmaceutica que lo comprende; combinacion farmaceutica; y su uso para el tratamiento o profilaxis de una enfermedad infecciosa. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL200400303A CL2004000303A1 (es) | 2003-02-20 | 2004-02-19 | Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih. |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US7585870B2 (es) |
| EP (2) | EP1603887B1 (es) |
| JP (2) | JP4586014B2 (es) |
| KR (2) | KR20050094896A (es) |
| CN (2) | CN100572364C (es) |
| AP (1) | AP2005003373A0 (es) |
| AR (2) | AR044500A1 (es) |
| AT (2) | ATE506353T1 (es) |
| AU (2) | AU2004213186B2 (es) |
| BR (2) | BRPI0407741B8 (es) |
| CA (2) | CA2516699C (es) |
| CL (2) | CL2004000303A1 (es) |
| CY (1) | CY1106788T1 (es) |
| DE (2) | DE602004006383T2 (es) |
| DK (1) | DK1597238T3 (es) |
| EA (2) | EA011256B1 (es) |
| ES (1) | ES2287734T3 (es) |
| HR (2) | HRP20050821A2 (es) |
| IL (2) | IL169596A (es) |
| MX (2) | MXPA05008867A (es) |
| MY (1) | MY138308A (es) |
| NO (2) | NO20054311L (es) |
| NZ (2) | NZ541601A (es) |
| PL (2) | PL226954B1 (es) |
| PT (1) | PT1597238E (es) |
| TW (2) | TW200510339A (es) |
| WO (2) | WO2004074262A1 (es) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| BR0313059B8 (pt) | 2002-07-29 | 2021-07-27 | Rigel Pharmaceuticals | composto, e, composição farmacêutica |
| CL2004000303A1 (es) * | 2003-02-20 | 2005-04-08 | Tibotec Pharm Ltd | Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih. |
| CN102358738A (zh) | 2003-07-30 | 2012-02-22 | 里格尔药品股份有限公司 | 2,4-嘧啶二胺化合物及其预防和治疗自体免疫疾病的用途 |
| US7456176B2 (en) | 2004-04-08 | 2008-11-25 | Targegen, Inc. | Benzotriazine inhibitors of kinases |
| US7652051B2 (en) | 2004-08-25 | 2010-01-26 | Targegen, Inc. | Heterocyclic compounds and methods of use |
| JP5095409B2 (ja) | 2004-11-24 | 2012-12-12 | ライジェル ファーマシューティカルズ， インコーポレイテッド | スピロ２，４−ピリミジンジアミン化合物およびその使用 |
| JP4801096B2 (ja) | 2005-01-19 | 2011-10-26 | ライジェル ファーマシューティカルズ， インコーポレイテッド | ２，４−ピリミジンジアミン化合物のプロドラッグおよびそれらの使用 |
| EP1904457B1 (en) | 2005-06-08 | 2017-09-06 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
| US20070203161A1 (en) | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
| US8604042B2 (en) | 2005-11-01 | 2013-12-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
| US7528143B2 (en) | 2005-11-01 | 2009-05-05 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
| US8133900B2 (en) | 2005-11-01 | 2012-03-13 | Targegen, Inc. | Use of bi-aryl meta-pyrimidine inhibitors of kinases |
| JP2009528295A (ja) | 2006-02-24 | 2009-08-06 | ライジェル ファーマシューティカルズ， インコーポレイテッド | Ｊａｋ経路の阻害のための組成物および方法 |
| CN106045965A (zh) * | 2006-12-29 | 2016-10-26 | 爱尔兰詹森科学公司 | 抑制hiv的5,6‑取代的嘧啶类化合物 |
| US9006243B2 (en) * | 2006-12-29 | 2015-04-14 | Janssen R&D Ireland | HIV inhibiting 6-substituted pyrimidines |
| EP2300013B2 (en) | 2008-05-21 | 2024-11-13 | Takeda Pharmaceutical Company Limited | Phosphorous derivatives as kinase inhibitors |
| US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
| TW201008933A (en) * | 2008-08-29 | 2010-03-01 | Hutchison Medipharma Entpr Ltd | Pyrimidine compounds |
| PE20110303A1 (es) | 2008-09-11 | 2011-05-21 | Pfizer | Derivados de heteroaril acetamidas como activadores de glucoquinasa |
| AR074210A1 (es) * | 2008-11-24 | 2010-12-29 | Boehringer Ingelheim Int | Derivados de pirimidina como inhibidores de ptk2-quinasa |
| TW201024281A (en) | 2008-11-24 | 2010-07-01 | Boehringer Ingelheim Int | New compounds |
| ES2427279T3 (es) | 2009-03-11 | 2013-10-29 | Pfizer Inc. | Derivados de benzofuranilo usados como inhibidores de glucocinasa |
| WO2012060847A1 (en) | 2010-11-07 | 2012-05-10 | Targegen, Inc. | Compositions and methods for treating myelofibrosis |
| US9249124B2 (en) | 2011-03-30 | 2016-02-02 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Aurora kinase inhibitors and methods of making and using thereof |
| EP2704572B1 (en) | 2011-05-04 | 2015-12-30 | Ariad Pharmaceuticals, Inc. | Compounds for inhibiting cell proliferation in egfr-driven cancers |
| GB201119358D0 (en) | 2011-11-10 | 2011-12-21 | Lewi Paulus J | Disubstituted triazine dimers for treatment and/or prevention of infectious diseases |
| GB201204756D0 (en) | 2012-03-19 | 2012-05-02 | Lewi Paulus J | Triazines with suitable spacers for treatment and/or prevention of HIV infections |
| JP6469567B2 (ja) | 2012-05-05 | 2019-02-13 | アリアド・ファーマシューティカルズ・インコーポレイテッド | Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物 |
| WO2014072419A1 (en) | 2012-11-08 | 2014-05-15 | Universiteit Antwerpen | Novel anti-hiv compounds |
| US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
| CN110818690B (zh) * | 2016-07-26 | 2021-08-10 | 深圳市塔吉瑞生物医药有限公司 | 用于抑制蛋白酪氨酸激酶活性的氨基嘧啶类化合物 |
| CN106749203B (zh) * | 2016-11-28 | 2020-04-10 | 洛阳聚慧医药科技有限公司 | 一种嘧啶类杂环化合物、嘧啶类杂环化合物盐以及制备方法和应用 |
| EP3966206B1 (en) | 2019-05-10 | 2023-08-09 | Deciphera Pharmaceuticals, LLC | Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof |
| EP3966207B1 (en) | 2019-05-10 | 2023-11-01 | Deciphera Pharmaceuticals, LLC | Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof |
| JP7626722B2 (ja) | 2019-06-17 | 2025-02-04 | デシフェラ・ファーマシューティカルズ，エルエルシー | アミノピリミジンアミドオートファジー阻害剤およびその使用方法 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3459731A (en) * | 1966-12-16 | 1969-08-05 | Corn Products Co | Cyclodextrin polyethers and their production |
| US5691364A (en) * | 1995-03-10 | 1997-11-25 | Berlex Laboratories, Inc. | Benzamidine derivatives and their use as anti-coagulants |
| HUP9900730A3 (en) | 1995-11-23 | 2001-04-28 | Janssen Pharmaceutica Nv | Solid mixtures of cyclodextrins prepared via melt-extrusion |
| NO311614B1 (no) * | 1996-10-01 | 2001-12-17 | Janssen Pharmaceutica Nv | Substituerte diamino-1,3,5-triazinderivater |
| GB9705361D0 (en) | 1997-03-14 | 1997-04-30 | Celltech Therapeutics Ltd | Chemical compounds |
| AU751573C (en) * | 1998-03-27 | 2003-10-09 | Janssen Pharmaceutica N.V. | HIV inhibiting pyrimidine derivatives |
| EP0945447A1 (en) * | 1998-03-27 | 1999-09-29 | Janssen Pharmaceutica N.V. | Trisubstituted 1,3,5-triazine derivatives for treatment of HIV infections |
| JP3635238B2 (ja) * | 1998-11-10 | 2005-04-06 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Ｈｉｖの複製を阻害するピリミジン類 |
| GB9828511D0 (en) * | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
| NZ513639A (en) | 1999-04-15 | 2004-02-27 | Bristol Myers Squibb Co | Cyclic protein tyrosine kinase inhibitors |
| GB9914258D0 (en) | 1999-06-18 | 1999-08-18 | Celltech Therapeutics Ltd | Chemical compounds |
| DE60025837T2 (de) * | 1999-09-24 | 2006-11-02 | Janssen Pharmaceutica N.V. | Antivirale feste dispersionen |
| JP2003511378A (ja) * | 1999-10-07 | 2003-03-25 | アムジエン・インコーポレーテツド | トリアジン系キナーゼ阻害薬 |
| US7276510B2 (en) | 2000-05-08 | 2007-10-02 | Janssen Pharmaceutica, Inc. | HIV replication inhibitors |
| WO2002036578A2 (en) * | 2000-10-31 | 2002-05-10 | Lynn Bonham | Triazine derivatives as lpaat-b inhibitors and uses thereof |
| JO3429B1 (ar) | 2001-08-13 | 2019-10-20 | Janssen Pharmaceutica Nv | مشتقات برميدينات مثبطة فيروس الايدز |
| TWI329105B (en) * | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| US7375222B2 (en) * | 2002-02-05 | 2008-05-20 | Astellas Pharma Inc. | 2,4,6-Triamino-1,3,5-triazine derivative |
| AR039540A1 (es) * | 2002-05-13 | 2005-02-23 | Tibotec Pharm Ltd | Compuestos microbicidas con contenido de pirimidina o triazina |
| EP1518855B1 (en) * | 2002-06-28 | 2011-10-26 | Astellas Pharma Inc. | Diaminopyrimidinecarboxa mide derivative |
| BR0313059B8 (pt) * | 2002-07-29 | 2021-07-27 | Rigel Pharmaceuticals | composto, e, composição farmacêutica |
| CL2004000303A1 (es) * | 2003-02-20 | 2005-04-08 | Tibotec Pharm Ltd | Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih. |
-
2004
- 2004-02-19 CL CL200400303A patent/CL2004000303A1/es unknown
- 2004-02-19 CL CL200400306A patent/CL2004000306A1/es unknown
- 2004-02-20 BR BRPI0407741A patent/BRPI0407741B8/pt not_active IP Right Cessation
- 2004-02-20 HR HR20050821A patent/HRP20050821A2/xx not_active Application Discontinuation
- 2004-02-20 TW TW093104175A patent/TW200510339A/zh unknown
- 2004-02-20 HR HR20050820A patent/HRP20050820A2/xx not_active Application Discontinuation
- 2004-02-20 AU AU2004213186A patent/AU2004213186B2/en not_active Ceased
- 2004-02-20 EA EA200501327A patent/EA011256B1/ru not_active IP Right Cessation
- 2004-02-20 TW TW093104173A patent/TW200500346A/zh unknown
- 2004-02-20 WO PCT/EP2004/050177 patent/WO2004074262A1/en not_active Ceased
- 2004-02-20 PL PL378064A patent/PL226954B1/pl unknown
- 2004-02-20 CA CA2516699A patent/CA2516699C/en not_active Expired - Fee Related
- 2004-02-20 EA EA200501326A patent/EA010423B1/ru not_active IP Right Cessation
- 2004-02-20 AR ARP040100549A patent/AR044500A1/es not_active Application Discontinuation
- 2004-02-20 EP EP04737251A patent/EP1603887B1/en not_active Expired - Lifetime
- 2004-02-20 WO PCT/EP2004/050175 patent/WO2004074261A1/en not_active Ceased
- 2004-02-20 BR BRPI0407732-6A patent/BRPI0407732A/pt not_active Application Discontinuation
- 2004-02-20 AR ARP040100548A patent/AR044499A1/es not_active Application Discontinuation
- 2004-02-20 ES ES04737252T patent/ES2287734T3/es not_active Expired - Lifetime
- 2004-02-20 MY MYPI20040575A patent/MY138308A/en unknown
- 2004-02-20 NZ NZ541601A patent/NZ541601A/en unknown
- 2004-02-20 PL PL378136A patent/PL227295B1/pl unknown
- 2004-02-20 KR KR1020057014231A patent/KR20050094896A/ko not_active Ceased
- 2004-02-20 DE DE602004006383T patent/DE602004006383T2/de not_active Expired - Lifetime
- 2004-02-20 KR KR1020057014648A patent/KR20050099994A/ko not_active Ceased
- 2004-02-20 EP EP04737252A patent/EP1597238B1/en not_active Expired - Lifetime
- 2004-02-20 JP JP2006502042A patent/JP4586014B2/ja not_active Expired - Fee Related
- 2004-02-20 AU AU2004213187A patent/AU2004213187B2/en not_active Ceased
- 2004-02-20 AP AP2005003373A patent/AP2005003373A0/xx unknown
- 2004-02-20 DE DE602004032321T patent/DE602004032321D1/de not_active Expired - Lifetime
- 2004-02-20 MX MXPA05008867A patent/MXPA05008867A/es active IP Right Grant
- 2004-02-20 DK DK04737252T patent/DK1597238T3/da active
- 2004-02-20 JP JP2006502041A patent/JP4586013B2/ja not_active Expired - Fee Related
- 2004-02-20 AT AT04737251T patent/ATE506353T1/de not_active IP Right Cessation
- 2004-02-20 PT PT04737252T patent/PT1597238E/pt unknown
- 2004-02-20 AT AT04737252T patent/ATE361915T1/de not_active IP Right Cessation
- 2004-02-20 NZ NZ542428A patent/NZ542428A/en unknown
- 2004-02-20 US US10/545,719 patent/US7585870B2/en not_active Expired - Lifetime
- 2004-02-20 CN CNB2004800043162A patent/CN100572364C/zh not_active Expired - Fee Related
- 2004-02-20 US US10/545,358 patent/US7442705B2/en not_active Expired - Lifetime
- 2004-02-20 MX MXPA05008866A patent/MXPA05008866A/es active IP Right Grant
- 2004-02-20 CN CN2004800043209A patent/CN1751031B/zh not_active Expired - Fee Related
- 2004-02-20 CA CA2516589A patent/CA2516589C/en not_active Expired - Fee Related
-
2005
- 2005-07-07 IL IL169596A patent/IL169596A/en active IP Right Grant
- 2005-07-12 IL IL169647A patent/IL169647A/en active IP Right Grant
- 2005-09-19 NO NO20054311A patent/NO20054311L/no not_active Application Discontinuation
- 2005-09-19 NO NO20054312A patent/NO20054312L/no not_active Application Discontinuation
-
2007
- 2007-08-03 CY CY20071101039T patent/CY1106788T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2004000930A1 (es) | Compuesto derivado de dihidroquinazolina de formula definida, util para el tratamiento y/o profilaxis de infecciones virales; composicion farmaceutica que comprende al compuesto y uso del compuesto en la preparacion de medicamentos. | |
| CL2004001069A1 (es) | Compuestos derivados de 1-benzoil-isoquinolinas sustituidos; procedimiento de preparacion, composicion farmaceutica; y uso para el tratamiento o profilaxis de diabetes tipo ii. | |
| CL2007001630A1 (es) | Compuestos derivados de pirrolidinamida; composicion farmaceutica; y uso para el tratamiento de la hepatitis c. | |
| CL2007003244A1 (es) | Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer. | |
| CL2007003299A1 (es) | Compuestos derivados de macrociclos, inhibidores del virus de la hepatitis c; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c. | |
| CL2008000377A1 (es) | Compuestos derivados de ciclos fusionados sustituidos; agente farmaceutico que comprende a dichos compuestos; y uso para la prevencion o tratamiento de la diabetes. | |
| CL2007002649A1 (es) | Composicion farmaceutica que comprende 2-[6-(3-amino-piperidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro-2h-pirimidin-1-ilmetil]-4-fluoro-benzonitrilo; y uso para el tratamiento de la diabetes. | |
| CL2007003033A1 (es) | Compuestos derivados de benzoilamino heterociclos; procedimiento de preparacion; composicion farmaceutica que lo comprende; y uso del compuesto en el tratamiento de la diabetes tipo ii. | |
| BRPI0818804A2 (pt) | Composto derivado de pirimidina, composição farmacêutica que o compreende e uso desse composto. | |
| CL2008002295A1 (es) | Compuestos derivados de tiazolida sustituidos con alquilsulfonilos; composicion farmaceutica; y uso para el tratamiento de la hepatitis c. | |
| CL2007003686A1 (es) | Compuestos derivados de indol con anillo unido en las posiciones 4,5; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para tratar una infeccion viral. | |
| BRPI0312649A2 (pt) | compostos, composições farmacêuticas contendo os mesmos, e processos de uso para os mesmos. | |
| CL2013000727A1 (es) | Compuestos derivados de nucleosidos de imidazo[1,2-f][1,2,4]triazinilo; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion por virus flaviviridae, particularmente infecciones por el virus de la hepatitis c. | |
| CL2007003138A1 (es) | Compuestos derivados de anilinopiperazina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer. | |
| BRPI0716495A2 (pt) | (r,r)-fenoterol e análogos de (r,r)- ou (r,s)-fenoterol, uso dos mesmos na preparação de composição farmacêutica e composição farmacêutica compreendendo o referidos compostos. | |
| CL2007002671A1 (es) | Compuestos derivados de octahidro-pirrolo[3,4-c]pirrol; composicion farmaceutica que la comprende; y uso del compuesto en el tratamiento del vih, sida o arc. | |
| CL2004000303A1 (es) | Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih. | |
| CL2008000409A1 (es) | Compuestos derivados de 2-(4 amino-pirrolo-piridin) furan-3,4 diol; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento y/o prevencion de infecciones virales. | |
| CL2007002920A1 (es) | Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos. | |
| CL2008000254A1 (es) | Compuestos derivados de 6-oxo-6,7-dihidro-5h-dibenzo-[b,d]azepin-7-ilo; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de la enfermedad de alzheimer o cancer. | |
| BRPI0717369A2 (pt) | Composto, medicamento, composição farmacêutica que o contém e uso do composto. | |
| CL2008002353A1 (es) | Compuestos derivados de 7h-indolo[2,1-a][2]benzazepina; composicion farmaceutica; y uso en el tratamiento de la hepatitis c. | |
| CL2004001365A1 (es) | Compuestos derivados de 3-fluoropiperidina; composicion farmaceutica que lo comprende; y uso del compuesto para tratar o prevenir el dolor o la enfermedad de parkinson. | |
| CL2007002511A1 (es) | Compuestos derivados de pirrolo[2,3-f]isoquinolina, inhibidores de cinasa-2; proceso de preparacion; composicion farmaceutica; combinacion farmaceutica; y uso para el tratamiento de una enfermedad autoinmune. | |
| CL2007003044A1 (es) | Compuestos derivados de benzoxazina; composicion farmaceutica que los comprende; y uso para el tratamiento de un trastorno psicotico, bipolar, depresivo y abuso o dependencia de sustancias entre otros. |